Evidence map›Paper›PMID 40025608›Full record

ArticleOrphanet journal of rare diseases2025

Health outcomes following COVID-19 infection and vaccination in hereditary hemorrhagic telangiectasia.

Christopher M Tarulli, Xiayi Ma, Kamalprit Chokar, Nicholas T Vozoris, Marianne S Clancy, Marie E Faughnan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Christopher M TarulliToronto HHT Centre, Division of Respirology, Department of Medicine, St. Michael's Hospital and Li Ka Shing Knowledge Institute, University of Toronto, 30 Bond Street, Toronto, ON, M5B 1W8, Canada.
Xiayi MaToronto HHT Centre, Division of Respirology, Department of Medicine, St. Michael's Hospital and Li Ka Shing Knowledge Institute, University of Toronto, 30 Bond Street, Toronto, ON, M5B 1W8, Canada.
Kamalprit ChokarToronto HHT Centre, Division of Respirology, Department of Medicine, St. Michael's Hospital and Li Ka Shing Knowledge Institute, University of Toronto, 30 Bond Street, Toronto, ON, M5B 1W8, Canada.
Nicholas T VozorisToronto HHT Centre, Division of Respirology, Department of Medicine, St. Michael's Hospital and Li Ka Shing Knowledge Institute, University of Toronto, 30 Bond Street, Toronto, ON, M5B 1W8, Canada.
Marianne S ClancyCure HHT, Monkton, MD, USA.
Marie E FaughnanToronto HHT Centre, Division of Respirology, Department of Medicine, St. Michael's Hospital and Li Ka Shing Knowledge Institute, University of Toronto, 30 Bond Street, Toronto, ON, M5B 1W8, Canada. marie.faughnan@unityhealth.to.

Funding

Pettit Block-term grant, Division of Respirology, University of Toronto Pettit Block-term grant, Division of Respirology, University of Toronto
6 · The paper itself

Abstract

backgroundThere has been concern that individuals living with Hereditary Hemorrhagic Telangiectasia (HHT) could be at higher risk for poor outcomes if infected with SARS-CoV2, the virus that causes COVID-19 disease. As literature is lacking on outcomes on COVID-19 infection and vaccination in HHT, the objectives of this study were to determine and assess outcomes in HHT, as well as quantify vaccination rates and vaccination side effects in a large cohort of individuals with HHT.

methodIndividuals previously recruited to OUR HHT Registry at St. Michael's Hospital, Toronto were contacted for participation in this study. Data were collected during annual assessment through a series of questionnaires asking specifically about HHT complications, treatments, and symptom management, along with COVID infection and vaccination data.

resultsWe attempted to contact all 262 subjects recruited to the registry. Of these, 215 (82.1%) responded at least once regarding COVID-19 related inquiries between April 2020 and August 2022, and these individuals formed our study sample. Forty-nine COVID-19 infections were reported in 47/215 (21.9%) individuals. Among 47 patients with recorded COVID-19 infection, 2/47 (4.3%) required urgent care and 7/47 (14.9%) were hospitalized following infection. Of the 7 individuals who were hospitalized, 3 (42.9%) required new supplemental oxygen. Zero deaths were reported due to COVID-19 infection. COVID vaccination history was available in 147/215 (68.4%). Of these, 135/147 (91.8%) of individuals reported vaccination and side effects were mild. DISCUSSION: While our sample population is much like the general HHT population with regards to gender, HHT symptoms, and genetics, study limitations including survivor bias, lack of vaccine effectiveness assessment, and participant reported data should be acknowledged.

conclusionOur results suggest that HHT patients are not at higher risk of severe infection with COVID-19 compared to the general population. Vaccination rates are high with only mild side effects being observed.

Indexed as

COVID-19COVID-19 VaccinesTelangiectasia, Hereditary HemorrhagicVaccinationAdultAgedFemaleHumansMaleMiddle AgedRegistriesSARS-CoV-2Young AdultCOVID-19 VaccinesCOVIDHHTVaccination

Identifiers

PMID40025608
PMCPMC11871591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.